Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Baiyunshan Pharmaceutical To Lead Establishment Of New Drug Innovation Center

This article was originally published in PharmAsia News

Executive Summary

Helmed by the Guangdong government, leading pharmaceutical companies in the province are jointly investing RMB 100 million ($14.5 million) to set up a new drug innovation company and a privately operated non-commercial drug innovation center in southern China. Baiyunshan Pharmaceutical intends to lead the establishment of the new firm and will raise RMB 5 million independently to secure 5 million shares or 5 percent of the entity. Baiyunshan believes the investment will bring new development opportunities: the understanding and acquisition of latest R&D information and dynamics of the industry; the sharing of the core technology platform of the new drug center; and priority in getting the center's R&D transfer rights. (Click here for more - Chinese Language)



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts